In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Corp.

www.celgene.com

Latest From Celgene Corp.

Five Companies To Watch This ASCO

MacroGenics, Amgen, Celgene, Forty Seven and Iovance are all set to enjoy a good ASCO meeting with promising data for key products revealed in the abstract drop.

Cancer ASCO

Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA

Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.

Gene Therapy ImmunoOncology

Bluebird Lays Some New Eggs, But They'll Take Time To Hatch

Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.

Gene Therapy ImmunoOncology

Vertex Targeting Protein Degradation In $1bn Kymera Deal

Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.

 

Deals Research and Development Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register